


Momelotinib Clinical Development Program: Overview

Momelotinib: An Inhibitor of JAK1, JAK2 and ACVR1

Momelotinib is an investigational agent in development for the treatment of myelofibrosis.



Development History

A Significant Number of Patients with MF Have Received Extended Momelotinib Therapy to Date



Key Clinical Trials


SIMPLIFY-1	SIMPLIFY-2	MOMENTUM MYELOFIBROSIS CLINICAL TRIAL	XAP
PHASE 3 CLINICAL TRIAL	PHASE 3 CLINICAL TRIAL	PHASE 3 CLINICAL TRIAL	EXTENDED ACCESS PROGRAM
JAKi-naïve patients (n=432) randomized 1:1 to momelotinib or ruxolitinib	Prior ruxolitinib-treated myelofibrosis patients (n=156) randomized 2:1 to momelotinib or best available therapy	Ongoing pivotal study with ~180 subjects	Ongoing with some patients receiving momelotinib for more than 10 years
COMPLETED	COMPLETED	Currently Enrolling	Ongoing >10 years

Data from Phase 1, 2, and 3 clinical trials demonstrate potential clinical activity and support further clinical development of momelotinib.



The actively enrolling **MOMENTUM Phase 3 Clinical Trial** aims to determine the activity of momelotinib on the key disease manifestations of myelofibrosis including symptomatology, anemia, and splenomegaly.

Visit: www.momentumtrial.com or www.clinicaltrials.gov for more information.



*Early crossover to open label in the event of confirmed symptomatic splenic progression

Danazol has been selected as an appropriate treatment comparator given its use to ameliorate anemia in MF patients, as recommended by NCCN and ESMO guidelines.

References:

- Mesa et al. Simplify-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis. *J Clin Oncol.* 2017;35(34):3844–50.
- Harrison et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. *Lancet Haematol.* 2018;5(2):e73–81.
- Oh et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. *Blood Adv.* 2020;4(18):4282–4291.

For more information, please visit www.sierraoncology.com

FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY; Momelotinib is an investigational agent not yet approved by the US FDA or any regulatory authority

